Tema ETF Trust Tema Heart & Health ETF

HRTS
$36.48 0.00 (0.00%)
Dividend Yield 1.3%
Payout Frequency Yearly

Dividend History

Pay DateAmountEx-DateRecord Date
December 11, 2025$0.472025-12-102025-12-10
December 12, 2024$0.472024-12-112024-12-11

Dividends Summary

Company News

EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
Benzinga • Piero Cingari • September 25, 2024

Novo Nordisk faces political pressure over high U.S. prices for its weight-loss drugs, Ozempic and Wegovy, ahead of the 2024 election. The company's CEO blamed pharmacy benefit managers (PBMs) for the high consumer costs, despite potential manufacturer price reductions.

ETFs to Profit from the Weight Loss Drug Boom
Zacks Investment Research • Neena Mishra • June 4, 2024

The market for GLP-1 drugs could soar to $130 billion by 2030

Play These New ETFs to Tap Lucrative Weight Loss Drug Market
Zacks Investment Research • Sanghamitra Saha • May 22, 2024

Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.

Healthcare ETFs for the Weight-Loss Drug Boom & Beyond
Zacks Investment Research • Neena Mishra • April 8, 2024

We discuss attractive investment opportunities within the healthcare industry.

Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing
Benzinga • Johnny Rice • January 29, 2024

David Song, PM of the Cardiovascular and Metabolic ETF (NASDAQ: HRTS) for Tema ETFs, was recently interviewed by Benzinga. Tema is an active investment adviser focused on differentiated strategies managed by experienced investment professionals offered through ETFs and SMAs. ...Full story available on Benzinga.com

Related Companies